AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of its wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in early Parkinson’s disease (PD).
– Results show, for the first time, that targeting underlying a-syn pathology with an active immunotherapy could slow the rate of progression of Parkinson’s disease
– Clear safety profile with no clinically relevant safety issues reported
– Targets met for immunogenicity (100% responder rate), pharmacodynamic effect, target engagement and clinical assessments
– Underlines potential and importance of active immunotherapies in precision medicine for neurodegenerative diseases
– AC Immune to host webcast and conference call today at 9:00am ET / 15:00 CET details below